Stimulant use disorder: Difference between revisions
From IDWiki
m (→: edited for clarity) |
(→: added citations, and treatments that don't work) |
||
| Line 90: | Line 90: | ||
*There is no good evidence in favour of any pharmacologic treatment, and medication-based treatment is generally not recommended |
*There is no good evidence in favour of any pharmacologic treatment, and medication-based treatment is generally not recommended |
||
**[[N-acetylcysteine]] may prevent relapse |
**[[N-acetylcysteine]] may prevent relapse[[CiteRef::nocito echevarria2017n-]] |
||
**[[Disulfiram]] may treat cocaine use disorders |
**[[Disulfiram]] may treat cocaine use disorders[[CiteRef::2010di]] |
||
**[[Modafinil]] may be useful |
**[[Modafinil]] may be useful[[CiteRef::sangroula2017mo]] |
||
**The following have not been found to be helpful: anticonvulsants[[CiteRef::minozzi2015an]][[CiteRef::alvarez2010an]] including topiramate[[CiteRef::singh2016to]], many stimulants[[CiteRef::2013ef]][[CiteRef::2016ps]][[CiteRef::bhatt2016ef]], dopamine agonists[[CiteRef::2015do]], antidepressants[[CiteRef::2011an]][[CiteRef::torrens2005ef]], and antipsychotics[[CiteRef::2016an]] |
|||
*The main focus is on psychosocial treatments, including [[contingency management]], [[cognitive behavioural therapy]], [[motivational interviewing]], [[relapse prevention]], and [[psychodynamic therapy]] |
*The main focus is on psychosocial treatments, including [[contingency management]], [[cognitive behavioural therapy]], [[motivational interviewing]], [[relapse prevention]], and [[psychodynamic therapy]] |
||
**Long-term abstinence is around 30 to 50% for people in treatment, with 40-50% dropout rate |
**Long-term abstinence is around 30 to 50% for people in treatment, with 40-50% dropout rate |
||
Revision as of 23:18, 14 July 2020
Background
- A substance use disorder that includes cocaine (freebase, crack, rock), methamphetamine (crystal meth, meth, crystal, jib, speed, ice, tina, side), and other amphetamine-like substances (including prescription stimulants)
| Stimulant | Mechanism | Half-life | Routes of administration |
|---|---|---|---|
| Cocaine | |||
| Powder cocaine | dopamine reuptake inhibitor | 30 to 120 minutes | snorted, but can be mixed with water and injected |
| Crack cocaine | smoked, but can be mixed with an acid and injected | ||
| Freebase | similar to crack, but may explode when smoked | ||
| Methamphetamine | |||
| Powder | dopamine reuptake inhibitor, also increases dopamine release | wide variability, about 10 to 30 hours | snorted or pressed into a pill and taken orally |
| Base | swallowed or injected | ||
| Crystal | smoked, dissolved and injected, or snorted | ||
Epidemiology
- Stimulants are the second-most commonly used illicit substances after marijuana
Pathophysiology
- All stimulants act mainly on the dopamine system
Clinical Manifestations
Acute intoxication
- Common symptoms include tachycardia or bradycardia, pupillary dilatation, high or low blood pressure, sweating, chills, nausea or vomiting, weight loss, psychomotor agitation or retardation, muscular weakness, respiratory depression, chest pain, arrhythmias, confusion, seizures, dyskinesia, dystonia, and coma
- Severe intoxication may cause mania, paranoia, severe delirium, hypertension, agitation, sweating, formication and skin picking, choreoathetosis, and ataxia
Stimulant-induced psychosis
- Schizophrenia complicates about 15 to 25% of chronic stimulant use within 2 to 5 years
- Unclear what the causal relationship is between stimulants and schizophrenia
Other sequelae
- Cardiovascular or cerebrovascular disease, including myocardial infarction, stroke, and acute kidney injury
- Psychiatric diseases including psychosis, depression, and suicidal ideation
- Increased risk of HIV and hepatitis C
- Death
Withdrawal
- Symptoms include depressed mood, vivid dreams, fatigue, insomnia, hypersomnia, cravings, psychomotor agitation or impairment, increased appetite, agitation, irritability, and cognitive impairment
Investigations
Urine drug screen
- Cocaine metabolites are detectable for about 3 to 5 days
- False positives: none
- Methamphetamines may be detectable for 3 to 5 days, with some variability
- False positives: nasal inhalers, ADHD medications, bupropion, trazodone, chlorpromazine, promethazine, ranitidine
Management
Intoxication
- Generally focussed on supportive care
Withdrawal
- Generally focussed on supportive care, including good nutrition
- Cognitive behavioural therapy and sleep hygiene may be helpful
Chronic treatment
- There is no good evidence in favour of any pharmacologic treatment, and medication-based treatment is generally not recommended
- The main focus is on psychosocial treatments, including contingency management, cognitive behavioural therapy, motivational interviewing, relapse prevention, and psychodynamic therapy
- Long-term abstinence is around 30 to 50% for people in treatment, with 40-50% dropout rate
- Contingency planning with or without cognitive behavioural therapy seems to be the most promising
References
- ^ Marco Antonio Nocito Echevarria, Tassio Andrade Reis, Giulianno Ruffo Capatti, Victor Siciliano Soares, Dartiu Xavier da Silveira, Thiago Marques Fidalgo. N-acetylcysteine for treating cocaine addiction – A systematic review. Psychiatry Research. 2017;251:197-203. doi:10.1016/j.psychres.2017.02.024.
- ^ Pier Paolo Pani, Emanuela Trogu, Rosangela Vacca, Laura Amato, Simona Vecchi, Marina Davoli. Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews. 2010. doi:10.1002/14651858.cd007024.pub2.
- ^ Dinesh Sangroula, Fatima Motiwala, Bivek Wagle, Vivek C. Shah, Katsuhiko Hagi, Steven Lippmann. Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis. Substance Use & Misuse. 2017;52(10):1292-1306. doi:10.1080/10826084.2016.1276597.
- ^ minozzi2015an
- ^ Yolanda Alvarez, Magí Farré, Francina Fonseca, Marta Torrens. Anticonvulsant drugs in cocaine dependence: A systematic review and meta-analysis. Journal of Substance Abuse Treatment. 2010;38(1):66-73. doi:10.1016/j.jsat.2009.07.001.
- ^ Mohit Singh, Dipinder Keer, Jan Klimas, Evan Wood, Dan Werb. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction. 2016;111(8):1337-1346. doi:10.1111/add.13328.
- ^ Clara Pérez-Mañá, Xavier Castells, Marta Torrens, Dolors Capellà, Magi Farre. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database of Systematic Reviews. 2013. doi:10.1002/14651858.cd009695.pub2.
- ^ Xavier Castells, Ruth Cunill, Clara Pérez-Mañá, Xavier Vidal, Dolors Capellà. Psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews. 2016. doi:10.1002/14651858.cd007380.pub4.
- ^ Meha Bhatt, Laura Zielinski, Lola Baker-Beal, Neera Bhatnagar, Natalia Mouravska, Phillip Laplante, Andrew Worster, Lehana Thabane, Zainab Samaan. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Systematic Reviews. 2016;5(1). doi:10.1186/s13643-016-0370-x.
- ^ Silvia Minozzi, Laura Amato, Pier Paolo Pani, Renata Solimini, Simona Vecchi, Franco De Crescenzo, Piergiorgio Zuccaro, Marina Davoli. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews. 2015. doi:10.1002/14651858.cd003352.pub4.
- ^ Pier Paolo Pani, Emanuela Trogu, Simona Vecchi, Laura Amato. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews. 2011. doi:10.1002/14651858.cd002950.pub3.
- ^ Marta Torrens, Francina Fonseca, Gerard Mateu, Magí Farré. Efficacy of antidepressants in substance use disorders with and without comorbid depression. Drug and Alcohol Dependence. 2005;78(1):1-22. doi:10.1016/j.drugalcdep.2004.09.004.
- ^ Blanca I Indave, Silvia Minozzi, Pier Paolo Pani, Laura Amato. Antipsychotic medications for cocaine dependence. Cochrane Database of Systematic Reviews. 2016. doi:10.1002/14651858.cd006306.pub3.
